Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

The Delhi High Court has allowed Zydus Lifesciences to sell its nivolumab biosimilar, citing public interest, while directing ...

Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data ...

Delhi High Court has cleared the way for Zydus Lifesciences to proceed with the sale of its version of the cancer drug ...

Stage 4 RCC is metastatic, with common spread to lungs, bones, liver, brain, and adrenal glands. Understanding IMDC risk is ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

Summit Therapeutics Inc. ( SMMT) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM EST ...

The court directed Zydus to maintain detailed and audited records of its sales during this period so that the innovator can ...

Novo Nordisk carries a Zacks Rank #5 (Strong Sell), whereas Amgen carries a Zacks Rank #3 (Hold) at present, which makes AMGN ...

As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...

The firm is looking ahead to Phase III Kimmtrak results in cutaneous melanoma and early-stage readouts from its PRAME candidates.

Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a single-digit decline ...